A Study of XMT-1660 in Participants With Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

319

Participants

Timeline

Start Date

August 15, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

May 31, 2027

Conditions
Triple Negative Breast CancerBreast CancerEndometrial CancerOvarian CancerFallopian Tube CancerPrimary Peritoneal Cavity CancerAdenoid Cystic Carcinoma
Interventions
DRUG

XMT-1660

XMT-1660 will be administered through a vein in your arm or port catheter (intravenously)

Trial Locations (23)

10016

RECRUITING

New York University Langone Health, New York

10029

NOT_YET_RECRUITING

ICHAN School of Medicine at Mount Sinai, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

22031

RECRUITING

NEXT Oncology Virginia, Fairfax

30322

RECRUITING

Winship Cancer Institute, Emory University, Atlanta

33612

RECRUITING

Moffitt Cancer Center, Tampa

34232

RECRUITING

Florida Cancer Specialists, Sarasota

37203

RECRUITING

Tennessee Oncology, PLLC, Nashville

48202

RECRUITING

Henry Ford Health Hospital, Detroit

57105

RECRUITING

Avera Cancer Institute, Sioux Falls

60611

RECRUITING

Northwestern University, Chicago

73104

RECRUITING

Stephenson Cancer Center Oklahoma University Health, Oklahoma City

75251

RECRUITING

Texas Oncology, P.A., Dallas

77030

RECRUITING

MD Anderson, Houston

84112

RECRUITING

Huntsman Cancer Institute, Salt Lake City

85054

RECRUITING

Mayo Clinic Comprehensive Cancer Center, Phoenix

89169

RECRUITING

Comprehensive Cancer Centers of Nevada, Las Vegas

90404

RECRUITING

UCLA, Santa Monica

92868

RECRUITING

UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange

94158

RECRUITING

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco

99208

RECRUITING

Summit Cancer Centers, Spokane

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Mersana Therapeutics

INDUSTRY

NCT05377996 - A Study of XMT-1660 in Participants With Solid Tumors | Biotech Hunter | Biotech Hunter